Recordati faces a €10.7 billion joint buyout bid. CVC Capital Partners and Groupe Bruxelles Lambert launched the proposal on Saturday. The offer aims to take the Milan-listed pharmaceutical company private. It represents one of the largest European healthcare acquisitions of the year.
Details of the Recordati Takeover Bid
The joint bid aims to take the Italian pharmaceutical company private. CVC Capital Partners already holds a significant indirect stake in the business, having previously invested in the company. The new offer, made in partnership with Belgian investment firm Groupe Bruxelles Lambert (GBL), seeks to acquire the remaining outstanding shares.
The €10.7 billion valuation reflects the scale of the transaction. The consortium plans to delist the company from the Milan stock exchange once the acquisition is complete. This will allow the new owners to restructure and expand the business away from the public markets.
Who are CVC and GBL
CVC Capital Partners is a prominent global private equity firm with a strong presence in Europe and growing operations in the Middle East. The firm manages billions of dollars in assets across various sectors, including healthcare, sports, and retail.
GBL is one of the largest holding companies in Europe, with a portfolio focused on long-term industrial investments. The Brussels-based firm has been actively diversifying its holdings, with a particular interest in stable, cash-generating sectors like healthcare and specialty chemicals.
The Growing Appeal of European Healthcare
The pharmaceutical sector remains highly attractive to private equity buyers. Companies like Recordati offer stable cash flows and steady demand, even during periods of broader economic uncertainty. The Italian drugmaker specialises in treatments for rare diseases and primary care, making it a valuable asset in the European market.
Global investors are increasingly looking at European healthcare firms for stable returns. The sector benefits from long-term demographic trends, including an aging population in Europe and rising healthcare spending globally. This transaction shows that large-scale private equity buyouts remain viable despite higher borrowing costs.
What Happens Next for the Deal
The proposed transaction will require regulatory approvals from European authorities before it can close. The board of Recordati will also need to review the offer and make a recommendation to its shareholders.
Industry analysts expect the deal to face close scrutiny from antitrust regulators, given the size of the companies involved. If approved, the acquisition will mark one of the most significant private equity deals in the European pharmaceutical sector in recent years.
